Heidelberg, Baden-Württemberg, Germany
I am Founder and CEO of Sciomics, a German precision proteomics company focused on robust protein biomarker discovery, translational research and high-content affinity proteomics. My long-term vision is enabling precision medicine by making protein-level insights and robust biomarker panels accessible for drug development, diagnostics and translational medicine. I developed and co-developed the antibody microarray platform underlying Sciomics’ technology at the German Cancer Research Center (DKFZ) and founded Sciomics in 2013 to translate this immuno-based proteomics approach into practical solutions for pharma, biotech, diagnostics and academic translational research. Today, Sciomics combines translational proteomics services with proprietary biomarker development programs. Our work supports biomarker discovery and verification, protein and PTM profiling, pathway and mode-of-action analysis, patient stratification, translational safety, advanced disease model profiling and preclinical R&D. In parallel, we are advancing proprietary protein biomarker panels, including scioAKI for early acute kidney injury diagnosis and scioPD1 for anti-PD-1 response and resistance prediction in melanoma. I am particularly interested in strategic pharma partnerships, diagnostic co-development, biomarker venture building and selected R&D collaborations where robust affinity proteomics can help translate biological complexity into actionable clinical and scientific insight.
Founded Sciomics to translate high-content antibody microarray technology into robust affinity proteomics services and protein biomarker development programs. Sciomics supports pharma, biotech, diagnostic and academic partners with protein and post-translational modification profiling for biomarker discovery, pathway analysis, mode-of-action studies, patient stratification, translational safety and advanced disease model characterization. In parallel, we are advancing proprietary protein biomarker panels for precision medicine applications, including acute kidney injury and immune checkpoint therapy response. Key focus areas: • Affinity proteomics and antibody microarray-based protein profiling • Protein biomarker discovery, verification and panel development • Translation of biomarker candidates into clinically applicable immunoassay formats • Protein and PTM profiling for preclinical and translational R&D • Strategic partnerships with pharma, biotech, diagnostic and investor partners Sciomics was founded in 2013 and has grown as a bootstrapped, science-driven company with a strong focus on precision medicine and translational impact.
REPO4EU is a European infrastructure initiative funded by the European Commission under Horizon Europe, aiming to build an industry-level platform for validated precision drug repurposing. As part of this initiative, Sciomics contributes expertise in affinity proteomics and protein biomarker development to support a deeper understanding of disease mechanisms and to help define biomarker strategies for patient stratification and precision therapy. My role focuses on translating protein-level disease insights into actionable biomarker concepts that can support drug repurposing, patient selection and mechanism-based therapeutic strategies.
Applied and further developed high-content antibody microarray technology for biomedical proteomics studies, with a focus on cancer biology and translational biomarker research. During this period, the platform was used in a variety of research projects, including studies in pancreatic cancer, bladder cancer, lymphoma and glioblastoma. The work contributed to establishing antibody microarrays as a robust affinity proteomics approach for protein profiling, biomarker discovery and pathway-level analysis.
Developed and optimized complex antibody microarray technology for sensitive and reproducible protein profiling. This work included systematic optimization of key experimental steps, assay parameters, sample processing, data quality and reproducibility, helping to establish antibody microarrays as a robust platform for high-content affinity proteomics.
Early research work on surface chemistries for antibody array applications, contributing to the technical foundation for later antibody microarray development.
Contributed to prospective technology study database at the European Commission’s Institute for Prospective Technological Studies, gaining early experience at the interface of science, innovation and technology assessment.